Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024
24 Oktober 2024 - 2:00PM
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage
pharmaceutical company dedicated to the global development and
commercialization of cytisinicline for the treatment of nicotine
dependence, today announced it will report its third quarter 2024
financial results and provide a corporate update on the
cytisinicline development program on Thursday, November 7, 2024, at
4:30 PM EST.
To access the webcast, please use the following link: 3Q24
Earnings Webcast. Alternatively, you may access the live conference
call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817
(International) and referencing conference ID 13749877. A webcast
replay will be available approximately three hours after the call
and archived on the website for 90 days.
About Achieve and Cytisinicline Achieve’s focus
is to address the global smoking health and nicotine addiction
epidemic through the development and commercialization of
cytisinicline. There are approximately 29 million adults and 2.25
million middle and high school students in the United States alone
who smoke combustible cigarettes. 1,2 Tobacco use is currently the
leading cause of preventable death that is responsible for more
than eight million deaths worldwide and nearly half a million
deaths in the United States annually. 3,4 More than 87% of
lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of
all deaths from coronary heart disease are attributable to smoking
and exposure to secondhand smoke. 3
In addition, there are over 11 million adults in the United
States who use e-cigarettes, also known as vaping. 5 In 2024,
approximately 1.6 million middle and high school students in the
United States reported using e-cigarettes. 6 Currently, there are
no FDA-approved treatments indicated specifically as an aid to
nicotine e-cigarette cessation.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in treating nicotine addiction for smoking and e-cigarette
cessation by interacting with nicotine receptors in the brain,
reducing the severity of nicotine craving symptoms, and reducing
the reward and satisfaction associated with nicotine products.
Cytisinicline is an investigational product candidate being
developed for the treatment of nicotine addiction and has not been
approved by the Food and Drug Administration for any indication in
the United States.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
timing and nature of cytisinicline clinical development and
regulatory review and approval, data results and commercialization
activities, the potential market size for cytisinicline, the
potential benefits, efficacy, safety and tolerability of
cytisinicline, the ability to discover and develop new uses for
cytisinicline, including but not limited to as an e-cigarette
cessation product, and the development and effectiveness of new
treatments. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements.
Achieve may not actually achieve its plans or product development
goals in a timely manner, if at all, or otherwise carry out its
intentions or meet its expectations or projections disclosed in
these forward-looking statements. These statements are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements, including, among others, the risk that
cytisinicline may not demonstrate the hypothesized or expected
benefits; the risk that Achieve may not be able to obtain
additional financing to fund the development of cytisinicline; the
risk that cytisinicline will not receive regulatory approval or be
successfully commercialized; the risk that new developments in the
smoking cessation landscape require changes in business strategy or
clinical development plans; the risk that Achieve’s intellectual
property may not be adequately protected; general business and
economic conditions; risks related to the impact on our business of
macroeconomic and geopolitical conditions, including inflation,
rising interest rates, increased volatility in the debt and equity
markets, actual or perceived instability in the global banking
system, global health crises and pandemics and geopolitical
conflict and the other factors described in the risk factors set
forth in Achieve’s filings with the Securities and Exchange
Commission from time to time, including Achieve’s Annual Reports on
Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable.
Investor Relations ContactRich
Cockrellachv@cg.capital(404) 736-3838
Media ContactGlenn
SilverGlenn.Silver@Finnpartners.com(646) 871-8485
References1 VanFrank B, Malarcher A, Cornelius
ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United
States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641. 2 Jamal A,
Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and
High School Students — National Youth Tobacco Survey, United
States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–9243 World
Health Organization. WHO Report on the Global Tobacco Epidemic,
2019. Geneva: World Health Organization, 2017. 4 U.S. Department of
Health and Human Services. The Health Consequences of Smoking – 50
Years of Progress. A Report of the Surgeon General, 2014. 5
Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among
Adults – United States, 2021. MMWR Morb Mortal Wkly Rep
2023;72:475–483. 6 Park-Lee E, Jamal A, Cowan H, et al. Notes from
the Field: E-Cigarette and Nicotine Pouch Use Among Middle and High
School Students — United States, 2024. MMWR Morb Mortal Wkly Rep
2024;73:774–778.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024